CRTX.L

CRISM Therapeutics Corporation
CRISM Therapeutics - Notice of Interim Results & IMC Presentation
9th September 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2974D
CRISM Therapeutics Corporation
09 September 2024
 

 

9 September 2024

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

Notice of Interim Results and Presentation via Investor Meet Company

 

CRISM Therapeutics Corporation (AIM: CRTX), the innovative UK drug delivery company focused on the localised delivery of chemotherapy drugs, will announce its Interim Results for the six months ended 30 June 2024 on Thursday, 19 September 2024.

Andrew Webb, CEO of CRISM Therapeutics, will provide a live presentation via Investor Meet Company on 19 September 2024 at 12.00pm BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 18 September 2024, 9.00am BST, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet CRISM Therapeutics via: https://www.investormeetcompany.com/crism-therapeutics-corporation/register-investor

Investors who already follow the Company on the Investor Meet Company platform will automatically be invited.

-Ends-

 

 

Enquiries:

 

Company

Nomad and Broker

Financial PR

CRISM Therapeutics Corporation

S.P. Angel Corporate Finance LLP

Burson Buchanan

Andrew Webb, CEO

Chris McConville, CSO

Richard Morrison

Adam Cowl

Mark Court / Jamie Hooper

CRISM@buchanancomms.co.uk

via Burson Buchanan

+44 (0) 20 3470 0470

+44 (0) 20 7466 5000

 

 

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high-grade glioma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

CRISM plans to submit a clinical trial application in H2 2024 for ChemoSeed® in high-grade glioma.  Based on preclinical data, the Tessa Jowell BRAIN MATRIX Scientific Advisory Board has approved ChemoSeed in a phase II platform clinical trial which is an efficient and cost-effective clinical development opportunity.

For more information please visit: https://www.crismtherapeutics.com/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORQKABDQBKDACK]]>
TwitterFacebookLinkedIn